StockTalks
-
MNTA is cheap if you factor in Copaxone launch in next 3 years and FOB partnership deal. Value of Copaxone itself >500m Oct 2, 2011
-
TRSX's (lead product:Tedizolid) seems like attractive reward/risk opportunity. Sep 28, 2011
-
bought MNTA at $19..i think attractive reward/risk Jun 1, 2011
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
















Full Index of Posts 4 posts, page 1 of 1
General Growth: Rebutting Shorts thesis - Part 2
Crisis - What we have lost, what we have not lost and the likely future
Laundry list of skewed incentives in US credit and capital markets
Money stock doubled in few months but still there is no sign of Inflation-Why??